Akari Therapeutics (AKTX) Short-Term Debt issuances (2024 - 2026)
Akari Therapeutics (AKTX) posted quarterly Short-Term Debt issuances of $102000.0 for Q1 2026, up 125.12% year-on-year from $45308.5 in Q1 2025, and down 89.67% on a QoQ basis from $987000.0 in Q4 2025.
Akari Therapeutics (AKTX) Short-Term Debt issuances (2024 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Short-Term Debt issuances for 3 consecutive years, with $102000.0 the latest figure, recorded in Q1 2026.
- Quarterly Short-Term Debt issuances rose 125.12% year-over-year to $102000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 108.06% YoY) and the FY2025 annual result came in at $499000.0, down 54.84% from the prior year.
- Short-Term Debt issuances slipped to $102000.0 in Q1 2026 per AKTX's latest filing, from $987000.0 in the prior quarter.
- Over the last five years, Short-Term Debt issuances for AKTX reached as high as $987000.0 in Q4 2025 and fell as low as -$406000.0 in Q1 2025.
- A 3-year average of $189555.6 and a median of $215000.0 in 2024 frame the typical range for Short-Term Debt issuances.
- The largest YoY upside for Short-Term Debt issuances was 342.6% in 2025 against a maximum downside of 288.84% in 2025.
- Year by year, Short-Term Debt issuances stood at $223000.0 in 2024, then jumped by 342.6% to $987000.0 in 2025, then slumped by 89.67% to $102000.0 in 2026.
- According to Business Quant data, Short-Term Debt issuances over the past three periods registered $102000.0, $987000.0, and -$33000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 58.20 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | 102,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Dec 31, 2025 | 987,000.00 |
| Dec 31, 2025 | 987,000.00 |
| Sep 30, 2025 | -33,000.00 |
| Sep 30, 2025 | -33,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -406,000.00 |
| Mar 31, 2025 | -406,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Mar 31, 2024 | 215,000.00 |